Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 3Colorectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 37Cytarabine 27Methotrexate 22Dexamethasone 20Vincristine 19fludarabine 15Mercaptopurine 14Etoposide 14Radiotherapy 12Daunorubicin 12Asparaginase 12Doxorubicin 11Prednisolone 9Idarubicin 9Busulfan 8pegaspargase 7blinatumomab 7Peripheral Blood Stem Cell Transplantation 6Melphalan 6Immunotherapy, Adoptive 6Imatinib Mesylate 6Dasatinib 6fludarabine phosphate 5Prednisone 5Methylprednisolone 5Filgrastim 5Whole-Body Irradiation 4Thioguanine 4Rituximab 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Automobiles × Clear all
NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 1 Unknown
33 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡